Riik: Iirimaa
keel: inglise
Allikas: HPRA (Health Products Regulatory Authority)
Amoxicillin
Athlone Laboratories Ltd
J01CA; J01CA04
Amoxicillin
500 milligram(s)
Capsule, hard
Product subject to prescription which may not be renewed (A)
Penicillins with extended spectrum; amoxicillin
Marketed
1988-06-29
00010 CCRF23053 PRAC PACKAGE LEAFLET: INFORMATION FOR THE USER PINAMOX 250 MG HARD CAPSULES PINAMOX 500 MG HARD CAPSULES Amoxicillin (as amoxicillin trihydrate) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you (or for your child) only. Do not pass it on to others. It may harm them even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Pinamox hard capsules are and what they are used for 2. What you need to know before you take Pinamox hard capsules 3. How to take Pinamox hard capsules 4. Possible side effects 5. How to store Pinamox hard capsules 6. Contents of the pack and other information 1. WHAT PINAMOX HARD CAPSULES ARE AND WHAT THEY ARE USED FOR WHAT PINAMOX HARD CAPSULES ARE Pinamox hard capsules are antibiotics. The active ingredient is amoxicillin. This belongs to a group of medicines called ‘penicillins’. WHAT PINAMOX HARD CAPSULES ARE USED FOR Pinamox hard capsules are used to treat infections caused by bacteria in different parts of the body. Pinamox hard capsules may also be used in combination with other medicines to treat stomach ulcers. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE PINAMOX HARD CAPSULES DO NOT TAKE PINAMOX HARD CAPSULES: • if you are allergic to amoxicillin, penicillin or any of the other ingredients of this medicine (listed in section 6). • if you have ever had an allergic reaction to any antibiotic. This can include a skin rash or swelling of the face or throat. 00010 CCRF23053 PRAC Do not take Pinamox hard capsules if any of the above apply. If you are not sure, talk to your doctor or pharmacist before taking Pinamox hard capsules. WARNINGS AND PRECAUTIONS Lugege kogu dokumenti
Health Products Regulatory Authority 08 March 2023 CRN00DG9T Page 1 of 13 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Pinamox 500mg hard Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains amoxicillin trihydrate equivalent to 500mg of amoxicillin. For a full list of excipients see section 6.1 3 PHARMACEUTICAL FORM Capsules, hard. Size zero elongated hard gelatin capsules with scarlet caps and ivory bodies, printed in black with a ‘P’ logo and ‘Pinamox 500’ and containing an off-white granular powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Pinamox is indicated for the treatment of the following infections in adults and children (see sections 4.2, 4.4 and 5.1): Acute bacterial sinusitis Acute otitis media Acute streptococcal tonsillitis and pharyngitis Acute exacerbations of chronic bronchitis Community acquired pneumonia Acute cystitis Asymptomatic bacteriuria in pregnancy Acute pyelonephritis Typhoid and paratyphoid fever Dental abscess with spreading cellulitis Prosthetic joint infections _Helicobacter pylori_ eradication Lyme disease Pinamox is also indicated for the prophylaxis of endocarditis. Consideration should be given to official guidance on the appropriate use of antibacterial agents. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The dose of Pinamox that is selected to treat an individual infection should take into account: The expected pathogens and their likely susceptibility to antibacterial agents (see section 4.4) The severity and the site of the infection The age, weight and renal function of the patient; as shown below The duration of therapy should be determined by the type of infection and the response of the patient, and should generally be as short as possible. Some infections require longer periods of treatment (see section 4.4 regarding prolonged therapy). Health Products Regulatory Authority 08 March 2023 CRN00DG9T Page 2 of 13 ADULTS AND CHILDREN ≥ 4 Lugege kogu dokumenti